Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
Implantable cardioverter defibrillators (ICDs) have been developed to treat ventricular
tachycardia or fibrillation (abnormal heart rhythms) by electrical shock or by pacing the
heart. ICD therapy is established as highly effective for stopping life-threatening
arrhythmias, but it does not preclude the use of anti-arrhythmic drugs for prevention and to
decrease the frequency of ICD shocks.
The safety and effectiveness of oral azimilide dihydrochloride in reducing the frequency of
ICD shocks has been investigated previously in a placebo-controlled study in patients with
ICDs. These results need to be confirmed in this larger double-blind, placebo-controlled
study with approximately 600 patients.